Burning Rock Biotech LtdNASDAQ:BNRNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE0.7514
- TODAY'S CHANGE (%)-0.0486 (-6.0750%)
- Bid / Lots0.7500/ 99
- Ask / Lots0.7528/ 1
- Open / Previous Close0.8201 / 0.8000
- Day Range
- 52 Week Range
- Volume3,892
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | BNR |
|---|---|---|
| 11:09 ET | 537 | 0.8201 |
| 12:32 ET | 100 | 0.7563 |
| 01:10 ET | 2900 | 0.7514 |
Mar 28, 2024
Burning Rock Reports Fourth Quarter and Full Year 2023 Financial Results, from 5:16PM ET on Thursday Mar 28, 2024 by Dow Jones
5:16PM ET on Thursday Mar 28, 2024 by Dow JonesPress Release: Burning Rock Reports Fourth Quarter and Full Year 2023 Financial Results, from 5:16PM ET on Thursday Mar 28, 2024 by Dow Jones
5:16PM ET on Thursday Mar 28, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Burning Rock Biotech Ltd | 82.1M | -0.9x | --- |
Ontrak Inc | 13.1M | 0.0x | --- |
PharmChem Inc | 12.6M | 18.6x | --- |
Novo Integrated Sciences Inc | 8.9M | -0.4x | --- |
Clearday Inc | 14.1M | -0.7x | --- |
Pacific Health Care Organization Inc | 9.3M | 19.7x | +17.15% |
Company Information
Burning Rock Biotech Ltd is a holding company mainly engaged in the next generation sequencing (NGS) based cancer therapy selection. The Company operates three segments. Central Laboratory Business segment is engaged in the sales of cancer therapy selection test to individual patients. In-Hospital Business segment is engaged in the sales of reagent kits and the provision of the facilitation services for the sale of laboratory equipment to hospitals. Pharma Research and Development Services segment provide services to companies primarily in relation to the development of targeted therapies and immunotherapies for various types of cancer, and to hospitals for their studies on cancer diagnosis and treatment. Its products include OncoScreen Plus and LungPlasma. Its NGS-based cancer therapy selection tests applicable to a broad range of cancer types, including lung cancer, prostate cancer, breast cancer and others. The Company mainly conducts its businesses in the China market.
Contact Information
- Headquarters
- No. 5 Xingdao Ring Road North , International Bio IslandGUANGZHOU, GNG, China 510005
- Phone
- ---
- Fax
- ---
Executives
- Chairman of the Board, Chief Executive Officer, Founder
- Yansheng Han
- Chief Financial Officer, Director
- Leo Li
- Chief Technology Officer, Director
- Zhihong Zhang
- Director
- Feng Deng
- Director
- Gang Lu
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $82.1M |
|---|---|
Revenue (TTM) | $74.2M |
Shares Outstanding | 102.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.15 |
EPS | $-0.88 |
Book Value | $1.03 |
P/E Ratio | -0.9x |
Price/Sales (TTM) | 1.1 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -124.54% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
